KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary (2025)
- Authors:
- Autor USP: ONUCHIC, LUIZ FERNANDO - FM
- Unidade: FM
- DOI: 10.1016/j.kint.2024.07.010
- Subjects: NEFROPATIAS; DIRETRIZES PARA O PLANEJAMENTO EM SAÚDE; RIM
- Language: Inglês
- Imprenta:
- Source:
- Título: Kidney international
- ISSN: 0085-2538
- Volume/Número/Paginação/Ano: v. 107, n. 2, p. 234-254, 2025
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: hybrid
- Licença: cc-by-nc-nd
-
ABNT
TORRES, Vicente E et al. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary. Kidney international, v. 107, n. 2, p. 234-254, 2025Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/82739. Acesso em: 09 jan. 2026. -
APA
Torres, V. E., Ahn, C., Barten, T. R. M., Brosnahan, G., Cadnapaphornchai, M. A., Chapman, A. B., et al. (2025). KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary. Kidney international, 107( 2), 234-254. doi:10.1016/j.kint.2024.07.010 -
NLM
Torres VE, Ahn C, Barten TRM, Brosnahan G, Cadnapaphornchai MA, Chapman AB, Gall EC-L, Drenth JPH, Gansevoort RT, Onuchic LF. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary [Internet]. Kidney international. 2025 ; 107( 2): 234-254.[citado 2026 jan. 09 ] Available from: https://observatorio.fm.usp.br/handle/OPI/82739 -
Vancouver
Torres VE, Ahn C, Barten TRM, Brosnahan G, Cadnapaphornchai MA, Chapman AB, Gall EC-L, Drenth JPH, Gansevoort RT, Onuchic LF. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary [Internet]. Kidney international. 2025 ; 107( 2): 234-254.[citado 2026 jan. 09 ] Available from: https://observatorio.fm.usp.br/handle/OPI/82739 - Expression of polyductin, the PKHD1 gene product, during normal and abnormal fetal development of the intrahepatic billiary sytem, billiary atresia, paucity of the intrahepatic biliary system and liver tumors
- Polyductin undergoes notch-like processing and regulated release from primary cilia
- Molecular and cellular pathogenesis of autosomal recessive polycystic kidney disease
- Haploinsufficiency for PKD1 results in increased tubularization of the bowman´s capsule and overexpression of COX-2
- Development of in vitro espression system of autosomal ressive polycystic kidney disease responsible gene (PKIID1) product, polydutin
- Inactivation of PKHD1 results in a liver phenotype characteristic of autosomal recessive polycystic kidney disease (ARPKD)
- Dendrogram Analyses of Relative Expression Between Bladder Cancers and Controls Identify PTEN-HIF1α Association as an Alteration Characteristic of Malignancy
- Infundibular stenosis in Bardet–Biedl syndrome
- Clinical aspects of autosomal recessive polycystic kidney disease
- Intragenic motifs regulate the transcriptional complexity of Pkhd1/PKHD1
Informações sobre o DOI: 10.1016/j.kint.2024.07.010 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
